Prevencio, a Kirkland, Washington-based biotechnology company, will partner with Atlas Genomics’ molecular diagnostic laboratory in Seattle to support the commercial rollout of Prevencio’s HART blood test technology.
Prevencio’s novel blood tests identify cardiovascular diseases and other heart-related risks by using machine learning to parse dozens of protein levels and other biomarkers at once, resulting in equally or more accurate results than traditional methods. The company is also developing tests for Kawasaki disease in partnership with Seattle Children’s Research Institute.